Cargando…
The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis
BACKGROUND: Family with sequence similarity 83 member H antisense RNA 1 (FAM83H-AS1) is a novel long non-coding RNA. Increasing studies have reported that FAM83H-AS1 is abnormally expressed in a variety of tumors and is associated with poor outcome. However, the clinical prognostic significance of l...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059312/ https://www.ncbi.nlm.nih.gov/pubmed/32165862 http://dx.doi.org/10.1186/s12935-020-1148-8 |
_version_ | 1783504024102764544 |
---|---|
author | Yang, Qin Wang, Jie Zhong, Pingyong Mou, Tinggang Hua, Hao Liu, Pan Xie, Fei |
author_facet | Yang, Qin Wang, Jie Zhong, Pingyong Mou, Tinggang Hua, Hao Liu, Pan Xie, Fei |
author_sort | Yang, Qin |
collection | PubMed |
description | BACKGROUND: Family with sequence similarity 83 member H antisense RNA 1 (FAM83H-AS1) is a novel long non-coding RNA. Increasing studies have reported that FAM83H-AS1 is abnormally expressed in a variety of tumors and is associated with poor outcome. However, the clinical prognostic significance of lncRNA FAM83H-AS1 in tumors is not completely known. METHODS: In this meta-analysis, literature was collected up until February 5, 2020 through multifarious retrieval strategies by searching through electronic databases of PubMed, Cochrane Library, EMBASE, Medline, Web of Science, CNKI, Weipu, and Wanfang. A total of 14 studies that met the inclusion criteria with relevant clinical data and prognostic information were included in the meta-analysis. RESULTS: The combined results revealed that high expression of FAM83H-AS1 was associated with poor overall survival (OS) (HR = 1.63, 95% CI 1.24–2.14, P = 0.0004) in a variety of cancers. Additionally, upregulated FAM83H-AS1 expression was significantly correlated with tumor TNM stage (III/IV vs. I/II, OR = 2.40, 95% CI 1.36–4.23, P = 0.003) and lymph node metastasis (positive vs. negative, OR = 1.70, 95% CI 1.14–2.52, P = 0.008) in patients with cancer. CONCLUSIONS: Our results of this meta-analysis indicated that elevated FAM83H-AS1 expression could predict poor prognosis in patients with cancer and suggested that FAM83H-AS1 might serve as a novel biomarker for cancer. |
format | Online Article Text |
id | pubmed-7059312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70593122020-03-12 The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis Yang, Qin Wang, Jie Zhong, Pingyong Mou, Tinggang Hua, Hao Liu, Pan Xie, Fei Cancer Cell Int Review BACKGROUND: Family with sequence similarity 83 member H antisense RNA 1 (FAM83H-AS1) is a novel long non-coding RNA. Increasing studies have reported that FAM83H-AS1 is abnormally expressed in a variety of tumors and is associated with poor outcome. However, the clinical prognostic significance of lncRNA FAM83H-AS1 in tumors is not completely known. METHODS: In this meta-analysis, literature was collected up until February 5, 2020 through multifarious retrieval strategies by searching through electronic databases of PubMed, Cochrane Library, EMBASE, Medline, Web of Science, CNKI, Weipu, and Wanfang. A total of 14 studies that met the inclusion criteria with relevant clinical data and prognostic information were included in the meta-analysis. RESULTS: The combined results revealed that high expression of FAM83H-AS1 was associated with poor overall survival (OS) (HR = 1.63, 95% CI 1.24–2.14, P = 0.0004) in a variety of cancers. Additionally, upregulated FAM83H-AS1 expression was significantly correlated with tumor TNM stage (III/IV vs. I/II, OR = 2.40, 95% CI 1.36–4.23, P = 0.003) and lymph node metastasis (positive vs. negative, OR = 1.70, 95% CI 1.14–2.52, P = 0.008) in patients with cancer. CONCLUSIONS: Our results of this meta-analysis indicated that elevated FAM83H-AS1 expression could predict poor prognosis in patients with cancer and suggested that FAM83H-AS1 might serve as a novel biomarker for cancer. BioMed Central 2020-03-06 /pmc/articles/PMC7059312/ /pubmed/32165862 http://dx.doi.org/10.1186/s12935-020-1148-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Yang, Qin Wang, Jie Zhong, Pingyong Mou, Tinggang Hua, Hao Liu, Pan Xie, Fei The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis |
title | The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis |
title_full | The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis |
title_fullStr | The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis |
title_full_unstemmed | The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis |
title_short | The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis |
title_sort | clinical prognostic value of lncrna fam83h-as1 in cancer patients: a meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059312/ https://www.ncbi.nlm.nih.gov/pubmed/32165862 http://dx.doi.org/10.1186/s12935-020-1148-8 |
work_keys_str_mv | AT yangqin theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT wangjie theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT zhongpingyong theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT moutinggang theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT huahao theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT liupan theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT xiefei theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT yangqin clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT wangjie clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT zhongpingyong clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT moutinggang clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT huahao clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT liupan clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis AT xiefei clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis |